Factor XIII, Functional
Use
Low Factor XIII levels (e.g., <15%) may cause a bleeding disorder, and levels below 2% have been associated with spontaneous intracranial hemorrhage. Reference interval is 57–192% activity, aiding in the diagnostic evaluation of coagulation disorders involving fibrin stabilization.
Special Instructions
Note oral anticoagulant therapy.
Limitations
This test uses a kit not cleared or approved by the FDA; analytical performance characteristics were determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. The test should not be used for diagnosis without confirmation by other medically established means.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 27815-0
- 27815-0
Result Turnaround Time
4-18 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL platelet‑poor plasma
Minimum Volume
0.5 mL
Container
Light-blue top (3.2% sodium citrate) tube; plastic vial for submission
Collection Instructions
Draw blood into a 3.2% sodium citrate (light blue‑top) tube. Centrifuge 15 minutes at ~1500 g within 60 minutes of collection. Using a plastic pipette, remove plasma, avoiding the WBC/platelet buffy layer, place into plastic vial. Centrifuge a second time and transfer platelet‑poor plasma into new plastic vial. Plasma must be free of platelets (<10,000/mcL). Freeze immediately, ship frozen.
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |